Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom

Last updated: August 26, 2025
Sponsor: Florida International University
Overall Status: Active - Not Recruiting

Phase

4

Condition

Attention Deficit/hyperactivity Disorder (Adhd - Adults)

Williams Syndrome

Treatment

General Classroom

Academic Accommodations

Methylphenidate Hydrochloride ER

Clinical Study ID

NCT05469386
800013424
  • Ages 5-12
  • All Genders

Study Summary

This study is the first to systematically evaluate the efficacy of single and combined academic accommodation, behavioral treatment, and medication treatment in a large sample of children with ADHD. Using a scientifically rigorous, cross-over design the impact of these approaches on ecologically valid measures of outcome (on-task behavior, quiz scores, academic productivity) will be assessed to inform effective school intervention.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • ADHD Diagnosis

  • IQ >= 70

Exclusion

Exclusion Criteria:

  • Prior adverse reaction to methylphenidate

  • Autism Spectrum disorder level 2/3

  • Child is home schooled

Study Design

Total Participants: 288
Treatment Group(s): 5
Primary Treatment: General Classroom
Phase: 4
Study Start date:
June 13, 2022
Estimated Completion Date:
August 31, 2026

Connect with a study center

  • FIU Center for Childern and Families

    Miami, Florida 33199
    United States

    Site Not Available

  • FIU Center for Childern and Families

    Miami 4164138, Florida 4155751 33199
    United States

    Site Not Available

  • Center for Children and Families

    Amherst, New York 14226
    United States

    Site Not Available

  • Center for Children and Families

    Amherst 5107129, New York 5128638 14226
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.